Back to News
Market Impact: 0.5
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
Source: prnewswire.com
Healthcare & BiotechLegal & LitigationCompany Fundamentals
EyePoint Pharmaceuticals shares lost nearly 80% of their value after disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky said it is investigating potential securities law violations on behalf of shareholders who lost money; the article does not report findings of wrongdoing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.75
Ticker Sentiment
EYPT-0.95
More News
- Stock Movers: CoreWeave, Cleveland Cliffs, EyePoint (Podcast)
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- LightStream stops accepting loan applications. Try these 6 lenders instead